Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Paul Maroni to Humans

This is a "connection" page, showing publications Paul Maroni has written about Humans.

 
Connection Strength
  
 
 
0.296
  
  1. Makedon A, Maroni P. Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer. Oncology (Williston Park). 2021 07 13; 35(7):422-424.
    View in: PubMed
    Score: 0.021
  2. Maroni P. Editorial Comment. J Urol. 2020 Oct; 204(4):810.
    View in: PubMed
    Score: 0.020
  3. Maroni PD. Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? Yes. Oncology (Williston Park). 2015 May; 29(5):348, 388.
    View in: PubMed
    Score: 0.014
  4. Maroni P. In germ cell cancer, are we at the end of the chemotherapy era? Maybe--and we are certainly at the end of the RCT era. Oncology (Williston Park). 2013 Nov; 27(11):1136, 1143.
    View in: PubMed
    Score: 0.012
  5. Maroni P, Phillips JM. Hopes and dreams for quality improvement in radical prostatectomy. Oncology (Williston Park). 2012 Jul; 26(7):630, 635.
    View in: PubMed
    Score: 0.011
  6. Crawford ED, O'Donnell CI, Barqawi AB, O'Leary M, Sullivan KF, Hughes A, Roehrborn CG, Maroni P. Validation of the modified American Urological Association symptom score. J Urol. 2011 Sep; 186(3):945-8.
    View in: PubMed
    Score: 0.011
  7. Maroni P, Crawford ED. Assessment of men before androgen deprivation therapy. J Urol. 2011 Aug; 186(2):371-2.
    View in: PubMed
    Score: 0.010
  8. Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract Res Clin Endocrinol Metab. 2008 Apr; 22(2):317-29.
    View in: PubMed
    Score: 0.008
  9. Maroni PD, Crawford ED. Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J. 2006 Mar-Apr; 67(2):136-9.
    View in: PubMed
    Score: 0.007
  10. Maroni PD, Crawford ED. Surgical management of prostate cancer: optimizing patient selections and clinical outcome. Surg Oncol Clin N Am. 2005 Apr; 14(2):301-19.
    View in: PubMed
    Score: 0.007
  11. Wiesen B, Atwell M, Leavitt C, Clark N, Kessler E, Lam E, Flaig T, Kukreja J, Kim S, Maroni P, Cost NG. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2024 Mar; 20(3):361-369.
    View in: PubMed
    Score: 0.006
  12. Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines? Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw. 2023 03; 21(3):236-246.
    View in: PubMed
    Score: 0.006
  13. Meier KM, Meyers ML, Fishbein L, Maroni PD, Cost NG. Multifocal Paraganglioma in Teenager Presenting With Hypertension. Urology. 2023 02; 172:192-195.
    View in: PubMed
    Score: 0.006
  14. Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 07; 61(7):717-734.
    View in: PubMed
    Score: 0.006
  15. Prasad RR, Raina K, Mishra N, Tomar MS, Kumar R, Palmer AE, Maroni P, Agarwal R. Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis. Mol Carcinog. 2022 05; 61(5):454-471.
    View in: PubMed
    Score: 0.005
  16. Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 12; 39(12):832.e9-832.e15.
    View in: PubMed
    Score: 0.005
  17. Sheridan A, Maroni P, Patel NU. Tips to start an MR-US fusion biopsy program. Abdom Radiol (NY). 2020 12; 45(12):4023-4027.
    View in: PubMed
    Score: 0.005
  18. Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 02; 27(1):10080-10085.
    View in: PubMed
    Score: 0.005
  19. Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr; 10(2):e82-e90.
    View in: PubMed
    Score: 0.005
  20. Aasen DM, Wiedel C, Maroni P, Cohen ME, Meng X, Meguid RA. Association of Hospital Altitude and Postoperative Infectious Complications After Major Operations. High Alt Med Biol. 2019 12; 20(4):421-426.
    View in: PubMed
    Score: 0.005
  21. Bidikov L, Maroni P, Kim S, Crawford ED. 67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential. Oncology (Williston Park). 2019 Sep 20; 33(9).
    View in: PubMed
    Score: 0.005
  22. Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
    View in: PubMed
    Score: 0.004
  23. Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 07; 58(7):1105-1117.
    View in: PubMed
    Score: 0.004
  24. Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct; 37(10):2099-2108.
    View in: PubMed
    Score: 0.004
  25. Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
    View in: PubMed
    Score: 0.004
  26. Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 07 15; 32(7):360-3, 369, CV3.
    View in: PubMed
    Score: 0.004
  27. Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glod? LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018 05; 78(7):506-511.
    View in: PubMed
    Score: 0.004
  28. Gore JL, du Plessis M, Santiago-Jim?nez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017 Aug 01; 123(15):2850-2859.
    View in: PubMed
    Score: 0.004
  29. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 06; 35(6):438-446.
    View in: PubMed
    Score: 0.004
  30. Stokes W, Amini A, Maroni PD, Kessler ER, Stokes C, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis. J Pediatr Urol. 2017 Aug; 13(4):386.e1-386.e7.
    View in: PubMed
    Score: 0.004
  31. Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology. 2016 11; 97:138-144.
    View in: PubMed
    Score: 0.004
  32. Amini A, Waxweiler TV, Maroni PD, Kessler ER, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Survival outcomes of adolescent and adult patients with non-seminomatous testicular germ-cell tumors: A population-based study. J Pediatr Urol. 2016 Dec; 12(6):405.e1-405.e9.
    View in: PubMed
    Score: 0.004
  33. Werahera PN, Jasion EA, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, Port JD, Daily JW, La Rosa FG. Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug; 2016:5148-5151.
    View in: PubMed
    Score: 0.004
  34. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016 May; 14(5):509-19.
    View in: PubMed
    Score: 0.004
  35. Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr; 15(2):136-46.
    View in: PubMed
    Score: 0.004
  36. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw. 2015 Dec; 13(12):1534-61.
    View in: PubMed
    Score: 0.004
  37. Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-1458.
    View in: PubMed
    Score: 0.004
  38. Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors. J Pediatr Hematol Oncol. 2015 Nov; 37(8):e441-6.
    View in: PubMed
    Score: 0.004
  39. Schlaepfer IR, Nambiar DK, Ramteke A, Kumar R, Dhar D, Agarwal C, Bergman B, Graner M, Maroni P, Singh RP, Agarwal R, Deep G. Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. Oncotarget. 2015 Sep 08; 6(26):22836-56.
    View in: PubMed
    Score: 0.003
  40. Schlaepfer IR, Glod? LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH. Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Mol Imaging Biol. 2015 Aug; 17(4):529-38.
    View in: PubMed
    Score: 0.003
  41. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219.
    View in: PubMed
    Score: 0.003
  42. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1064-73.
    View in: PubMed
    Score: 0.003
  43. Cost NG, Maroni P, Flaig TW. Metastatic relapse after initial clinical stage I testicular Leydig cell tumor. Oncology (Williston Park). 2014 Mar; 28(3):211, 214.
    View in: PubMed
    Score: 0.003
  44. Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Annu Int Conf IEEE Eng Med Biol Soc. 2014; 2014:2165-8.
    View in: PubMed
    Score: 0.003
  45. Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maroni P, Kiser JJ. Priapism induced by boceprevir-CYP3A4 inhibition and a-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan; 58(1):e35-8.
    View in: PubMed
    Score: 0.003
  46. Garrett K, Okuyama S, Jones W, Barnes D, Tran Z, Spencer L, Lewis K, Maroni P, Chesney M, Marcus A. Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program. Patient Educ Couns. 2013 Aug; 92(2):266-72.
    View in: PubMed
    Score: 0.003
  47. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87.
    View in: PubMed
    Score: 0.003
  48. Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011 Oct; 78(4):863-7.
    View in: PubMed
    Score: 0.003
  49. Koul HK, Kumar B, Koul S, Deb AA, Hwa JS, Maroni P, van Bokhoven A, Lucia MS, Kim FJ, Meacham RB. The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today (Barc). 2010 Dec; 46(12):929-43.
    View in: PubMed
    Score: 0.003
  50. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer. 2010 Jun 15; 9:148.
    View in: PubMed
    Score: 0.002
  51. Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S. A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma? Oncology (Williston Park). 2009 Feb; 23(2):177-80.
    View in: PubMed
    Score: 0.002
  52. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009 Sep 18; 282(2):125-36.
    View in: PubMed
    Score: 0.002
  53. Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene. 2009 Mar 05; 28(9):1248-60.
    View in: PubMed
    Score: 0.002
  54. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. Mol Cancer Res. 2008 Oct; 6(10):1639-48.
    View in: PubMed
    Score: 0.002
  55. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, Jones K, Moore R, Ogden LG, W?h?l? K, Sackett HM, Gray KJ. Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men. J Nutr. 2005 Jun; 135(6):1400-6.
    View in: PubMed
    Score: 0.002
  56. Koul HK, Maroni PD, Meacham RB, Crawford D, Koul S. p42/p44 Mitogen-activated protein kinase signal transduction pathway: a novel target for the treatment of hormone-resistant prostate cancer? Ann N Y Acad Sci. 2004 Dec; 1030:243-52.
    View in: PubMed
    Score: 0.002
  57. Mingin G, Maroni P, Gerharz EW, Woodhouse CR, Baskin LS. Linear growth after enterocystoplasty in children and adolescents: a review. World J Urol. 2004 Sep; 22(3):196-9.
    View in: PubMed
    Score: 0.002
  58. Gennari R, Dominioni L, Imperatori A, Bianchi V, Maroni P, Dionigi R. Alterations in lymphocyte subsets as prognosticators of postoperative infections. Eur J Surg. 1995 Jul; 161(7):493-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)